IQVIA (NYSE:IQV – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
Several other research analysts have also issued reports on the company. Evercore ISI dropped their price objective on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. The Goldman Sachs Group started coverage on IQVIA in a research note on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective for the company. Barclays dropped their price objective on IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday. Robert W. Baird dropped their price objective on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research note on Friday, May 3rd. Finally, Truist Financial dropped their price objective on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $257.73.
Check Out Our Latest Stock Analysis on IQVIA
IQVIA Stock Performance
IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. Sell-side analysts expect that IQVIA will post 10.11 EPS for the current year.
Hedge Funds Weigh In On IQVIA
Several hedge funds have recently added to or reduced their stakes in IQV. Los Angeles Capital Management LLC boosted its holdings in IQVIA by 17.5% during the fourth quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock worth $27,445,000 after buying an additional 17,677 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in IQVIA by 4.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after buying an additional 93,194 shares during the last quarter. Cadian Capital Management LP acquired a new stake in shares of IQVIA during the fourth quarter worth about $70,108,000. Nomura Holdings Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth about $857,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth about $13,759,000. Institutional investors own 89.62% of the company’s stock.
IQVIA Company Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
- Five stocks we like better than IQVIA
- What is a Special Dividend?
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Election Stocks: How Elections Affect the Stock Market
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.